Jump to section
To get effective therapies to patients faster by transforming clinical drug development with disruptive technologies.
78% employee growth in 12 months
Medable is aiming to transform the way clinical trials are conducted globally, digitizing the clinical trial process to ultimately cut trial timelines in half. It does this with its end-to-end, cloud based platform delivering a suite of tools for patients and clinical research organizations to work together more efficiently.
Medable, alongside its competitors such as Science 37, gained traction when the pandemic put a halt to thousands of trials, by stepping in with models removing the need for in-patient site visits and allowing complex research protocols to be conducted remotely. Demand for these platforms has not dwindled since, showing that the industry has a real need for products such as Medable's.
The company has seen good funding and made several high-profile collaborations, as well as launching its own Partner Network to propel the deployment of decentralized clinical trials. Collaborators in the network include the likes of Cognizant, Oracle, and PPD. The company has also been recognized as a leader and key innovator in the space, boding well for it future.
Freddie
Company Specialist at Welcome to the Jungle
Oct 2021
$304m
SERIES D
Apr 2021
$78m
SERIES C
This company has top investors
Michelle Longmire
(CEO)Previously a Postdoctoral Research Fellow at Stanford University School of Medicine for 2 years, and Research Fellow at Howard Hughes Medical Institute for 1 year.
Tim Smith
(CTO)Previously Director of Operations at ZTEC Instruments for 3 years and Co-Founder & CTO at ClosedWon for 6 years.
James Sas
(Chief Architect)Previously Game Programmer at Disney Interactive Studios for 6 months and Senior Developer at Basis Applied Technology for 8 years.